Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20257528 | 0.86 | TAAR1 (0.49) | ACHETAAR1IDH1PDE3BPDE3A | |
| SCHEMBL20713851 | 0.82 | ACHE (0.48) | ACHETAAR1IDH1P2RX7PDE3B | |
| SCHEMBL25609340 | 0.81 | MAOB (0.55) | ACHETAAR1IDH1IDO1AGXT | |
| SCHEMBL16191018 | 0.80 | TAAR1 (0.50) | ACHETAAR1IDH1P2RX7PDE3B | |
| SCHEMBL15280152 | 0.79 | ACHE (0.48) | ACHETAAR1IDH1P2RX7PDE3B | |
| SCHEMBL28127199 | 0.79 | ACHE (0.48) | ACHETAAR1IDH1IDO1AGXT | |
| SCHEMBL21928744 | 0.79 | PTPN1 (0.49) | ACHETAAR1IDO1MAPTMPO | |
| SCHEMBL22897738 | 0.77 | ACHE (0.46) | ACHETAAR1IDH1IDO1AGXT | |
| SCHEMBL22965336 | 0.77 | ACHE (0.46) | ACHETAAR1IDH1P2RX7PDE3B | |
| SCHEMBL2094961 | 0.76 | TAAR1 (0.48) | ACHETAAR1IDO1MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117899-B2 | [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2021-09-14 | — | — | US | disclosed |
| US-11066411-B2 | — | — | 2021-07-20 | — | — | US | disclosed |
| US-20200131184-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117899-B2 | [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor | ADORA2A, ADORA1, ADORA3 | ACHE 1905/4885TAAR1 43/4885IDH1 4194/4885 |
| US-11066411-B2 | — | ADORA2A, ADORA1, ADORA2B | ACHE 1479/4885TAAR1 47/4885IDH1 3801/4885 |
| US-20200131184-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | ADORA2A, ADORA1, ADORA3 | ACHE 1905/4885TAAR1 43/4885IDH1 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.